111, Inc. (YI)
Market Cap | 980.08M |
Revenue (ttm) | 564.58M |
Net Income (ttm) | -71.37M |
Shares Out | 82.36M |
EPS (ttm) | -1.27 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 22 |
Last Price | $11.90 |
Previous Close | $8.49 |
Change ($) | 3.41 |
Change (%) | 40.16% |
Day's Open | 8.75 |
Day's Range | 8.75 - 12.85 |
Day's Volume | 5,822,333 |
52-Week Range | 5.35 - 12.85 |
SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform company committed to digitally connecting patients with medicine ...
111, Inc. (YI) CEO Junling Liu on Q3 2020 Results - Earnings Call Transcript
SHANGHAI, Nov. 19, 2020 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform committed to digitally connecting patients with medicine and heal...
SHANGHAI, Oct. 19, 2020 /PRNewswire/ -- On September 24, 111, Inc. (the "Company" or "111") entered into a strategic partnership (the "Partnership") with Bayer Healthcare Co. Ltd. ("Bayer Heal...
SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (NASDAQ: YI) (the "Company" or "111") and Hainan Huluwa Pharmaceutical Group Co., Ltd. (SH: 605199) ("Huluwa Pharmaceutical")...
SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (NASDAQ: YI) ("111") and Shanghai Uniondrug Information Technology Co., Ltd ("Shanghai Uniondrug") officially signed a strate...
SHANGHAI, Sept. 30, 2020 /PRNewswire/ -- On September 24, 2020, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform dedicating to digitally connecting patien...
SHANGHAI, Sept. 4, 2020 /PRNewswire/ -- On August 25, 111, Inc.
111, Inc. (YI) CEO Junling Liu on Q2 2020 Results - Earnings Call Transcript
SHANGHAI, Aug. 20, 2020 /PRNewswire/ -- 111, Inc.
Completion of new capital injection in principal subsidiary Yao Fang Shanghai Initiation to list shares of principal subsidiary Yao Fang Shanghai on the STAR Market 111 firmly committed to mai...
SHANGHAI, July 31, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today...
111, Inc. (YI) CEO Junling Liu on Q1 2020 Results - Earnings Call Transcript
SHANGHAI, May 21, 2020 /PRNewswire/ --111, Inc. ("111" or the "Company") (NASDAQ: YI), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today a...
111, Inc. (YI) CEO Junling Liu on Q4 2019 Results - Earnings Call Transcript
111, Inc.'s (YI) CEO Junling Liu on Q3 2019 Results - Earnings Call Transcript
We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.
111, Inc. (YI) CEO Junling Liu on Q2 2019 Results - Earnings Call Transcript
111, Inc's (YI) CEO Junling Liu on Q1 2019 Results - Earnings Call Transcript
China's 111 Sees Boost From Healthcare Reform
One of China's leading online pharmacy and healthcare service providers says it will attract new partners as reforms take shape in the nation's healthcare market. 111 Inc. co-founder and Execu...
About YI
111, through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nu... [Read more...]
Industry Pharmaceutical Retailers | Founded 2010 |
Stock Exchange NASDAQ | Ticker Symbol YI |
Financial Performance
In 2019, 111, Inc.'s revenue was 3.95 billion, an increase of 121.28% compared to the previous year's 1.79 billion. Losses were -499.61 million, 31.4% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for 111, Inc. stock is "Strong Buy" and the 12-month stock price forecast is 12.00.